ClinicalTrialsFinder
RecruitingPhase 1NCT07318324

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

Sponsor

M.D. Anderson Cancer Center

Enrollment

31 participants

Start Date

May 13, 2026

Study Type

INTERVENTIONAL

Conditions

EndometrialPhase IBAvutometinibRAS Pathway

Summary

To find the recommended dose of the combination of avutometinib, defactinib, and everolimus in patients with endometrial cancer that is recurrent and has abnormal RAS activity. The safety and effects of this combination will also be studied.

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Avutometinib, a drug called Everolimus, and others for people with avutometinib, endometrial, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAvutometinib

Given by PO

DRUGdefactinib

Given by PO

DRUGEverolimus

Given by PO

Locations(1)

MD Anderson Cancer Center

Houston, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07318324

Related Trials

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

NCT071920684 locations